A Single Ascending Dose and Relative Bioavailability Study of LY2940680 in Healthy Subjects
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Taladegib (Primary) ; Lansoprazole; Taladegib
- Indications Basal cell cancer; Cancer; Oesophageal cancer; Small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly and Company
- 11 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Sep 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.